Jyong Biotech Ltd. Ordinary Shares (MENS) 10-Year Financial Performance & Capital Metrics

MENS • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutJyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiaries—Health Ever Bio-Tech, Genvace, and others—working on drug candidates like MCS‑2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stagesShow more

Revenue $0
EBITDA -$2M +27.5%
Net Income -$3M +31.4%
EPS (Diluted) -0.04 +31.4%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -1.99 +46.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-

EPS CAGR

10Y-

5Y-

3Y-

TTM-

ROCE

10Y Avg-40.87%

5Y Avg-40.87%

3Y Avg-

Latest-

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.55B	7.62	54.43	55.85%	3.98%	15.63%	0.35%	1.02
EXELExelixis, Inc.	12.13B	45.23	25.70	18.49%	29.63%	31.37%	5.23%	0.09
INBXInhibrx Biosciences, Inc.	1.1B	75.93	0.65	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.16B	6.31	-2.99		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.4B	8.07	-3.42	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.1B	11.25	-6.15			-33.24%		0.01
ZLABZai Lab Limited	2.17B	19.61	-7.54	49.59%	-46.83%	-27.21%		0.18
TNGXTango Therapeutics, Inc.	1.67B	12.39	-10.41	15.17%	-151.15%	-62.81%		0.18

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	0	121K	122K	127K	120K
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	-121K	-122K	-127K	-120K
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-	-0.01%	-0.04%	0.06%
Operating Expenses+	2.45M	2.4M	2.83M	2.8M	2.06M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	931K	845K	1.54M	1.73M	1.13M
SG&A % of Revenue	-	-	-	-	-
Research & Development	1.51M	1.56M	1.29M	1.07M	927K
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0
Operating Income+	-2.45M	-2.4M	-2.83M	-2.8M	-2.06M
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	0.02%	-0.18%	0.01%	0.26%
EBITDA+	-2.34M	-2.28M	-2.71M	-2.67M	-1.94M
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	0.02%	-0.19%	0.01%	0.27%
D&A (Non-Cash Add-back)	110K	122K	123K	127K	120K
EBIT	-2.45M	-3.36M	-5.87M	-3.64M	-1.98M
Net Interest Income+	-832K	-829K	-760K	-701K	-1.03M
Interest Income	0	6K	5K	56K	7K
Interest Expense	832K	835K	765K	757K	1.03M
Other Income/Expense	530K	-1.79M	-3.8M	-1.6M	-963K
Pretax Income+	-1.92M	-4.2M	-6.63M	-4.4M	-3.02M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%
Net Income+	-1.92M	-4.2M	-6.63M	-4.4M	-3.02M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-1.19%	-0.58%	0.34%	0.31%
Net Income (Continuing)	-1.92M	-4.2M	-6.63M	-4.4M	-3.02M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.03	-0.06	-0.09	-0.06	-0.04
EPS Growth %	-	-1.06%	-0.58%	0.34%	0.31%
EPS (Basic)	-0.03	-0.06	-0.09	-0.06	-0.04
Diluted Shares Outstanding	71.57M	76.03M	76.03M	76.03M	76.03M
Basic Shares Outstanding	71.57M	76.03M	76.03M	76.03M	76.03M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.22M	2.65M	2.46M	1.84M	206K
Cash & Short-Term Investments	4.22M	2.38M	812K	177K	98K
Cash Only	3.56M	551K	718K	177K	98K
Short-Term Investments	664K	1.83M	94K	0	0
Accounts Receivable	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	1.6M	263K	1.65M	1.66M	108K
Total Non-Current Assets+	6.62M	6.78M	6.28M	6.41M	6.16M
Property, Plant & Equipment	6.61M	6.78M	6M	3.54M	3.19M
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	10K	8K	283K	2.87M	2.97M
Total Assets+	12.84M	9.43M	8.74M	8.25M	6.37M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	-0.27%	-0.07%	-0.06%	-0.23%
Total Current Liabilities+	5.78M	6.29M	12.91M	14.26M	12.13M
Accounts Payable	25K	46K	4K	2K	3K
Days Payables Outstanding	-	138.76	11.97	5.75	9.13
Short-Term Debt	4.83M	4.93M	7.65M	7.97M	7.28M
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	151K	23K	4.22M	4.99M	3.33M
Current Ratio	1.08x	0.42x	0.19x	0.13x	0.02x
Quick Ratio	1.08x	0.42x	0.19x	0.13x	0.02x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	26.27M	26.46M	25.47M	28.06M	30.76M
Long-Term Debt	8.29M	6.26M	6.32M	8.52M	10.68M
Capital Lease Obligations	359K	346K	115K	69K	16K
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	17.62M	19.86M	19.04M	19.47M	20.06M
Total Liabilities	32.05M	32.76M	38.38M	42.32M	42.88M
Total Debt+	13.6M	11.79M	14.25M	16.69M	18.14M
Net Debt	10.04M	11.24M	13.53M	16.51M	18.04M
Debt / Equity	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-2.94x	-2.88x	-3.70x	-3.69x	-1.99x
Total Equity+	-19.2M	-23.32M	-29.63M	-34.07M	-36.52M
Equity Growth %	-	-0.21%	-0.27%	-0.15%	-0.07%
Book Value per Share	-0.27	-0.31	-0.39	-0.45	-0.48
Total Shareholders' Equity	-19.2M	-23.32M	-29.63M	-34.07M	-36.52M
Common Stock	1K	1K	1K	1K	1K
Retained Earnings	-14.83M	-19.03M	-25.66M	-30.06M	-33.08M
Treasury Stock	-16.37M	-16.37M	-16.37M	-16.37M	-16.37M
Accumulated OCI	189K	266K	590K	548K	1.12M
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.09M	-1.98M	-2.97M	-2.6M	-3.62M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-0.83%	-0.5%	0.12%	-0.39%
Net Income	-1.92M	-4.2M	-6.63M	-4.4M	-3.02M
Depreciation & Amortization	110K	122K	123K	127K	120K
Stock-Based Compensation	0	0	0	0	0
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	694K	849K	599K	554K	761K
Working Capital Changes	25K	1.24M	2.94M	1.12M	-1.49M
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	0	21K	-28K	-2K	1K
Cash from Investing+	731K	-1.31M	1.39M	95K	0
Capital Expenditures	-88K	-137K	-246K	0	0
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	819K	0	0	0	0
Cash from Financing+	4.91M	-1.38M	3.33M	2.03M	1.99M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	2.52M	-35K	-276K	-445K	-213K
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-1.18M	-2.12M	-3.22M	-2.6M	-3.62M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-0.81%	-0.52%	0.19%	-0.39%
FCF per Share	-0.02	-0.03	-0.04	-0.03	-0.05
FCF Conversion (FCF/Net Income)	0.57x	0.47x	0.45x	0.59x	1.20x
Interest Paid	88K	106K	162K	104K	223K
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Interest Coverage	-2.94x	-2.88x	-3.70x	-3.69x	-1.99x
FCF Conversion	0.57x	0.47x	0.45x	0.59x	1.20x

Frequently Asked Questions

Growth & Financials

Jyong Biotech Ltd. Ordinary Shares (MENS) grew revenue by 0.0% over the past year. Growth has been modest.

Jyong Biotech Ltd. Ordinary Shares (MENS) reported a net loss of $0.0M for fiscal year 2024.

Dividend & Returns

Jyong Biotech Ltd. Ordinary Shares (MENS) had negative free cash flow of $0.0M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener